Associated tags: TCR, Patient, HLA, Cancer, Therapy, Pharmaceutical industry, Society
Locations: WALTHAM, MA, US, NY, NEW YORK, CHRYSTAL
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 5, 2024 at 11:00 a.m. Eastern Time.
Key Points:
- WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 5, 2024 at 11:00 a.m. Eastern Time.
- A webcast of the presentation will be available on the “ Events and Presentations ” section of the Company’s website at ir.tscan.com .
- An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
HLA,
Antigen,
Patient,
MDS,
Investigational New Drug,
Food,
FDA,
IND,
Breakthrough therapy,
Therapy,
Drug development,
Disease,
TCR,
Malignancy,
Breakthrough,
AML,
HCT,
ALL,
Cancer,
Acute lymphoblastic leukemia,
Myelodysplastic syndrome,
Histocompatibility,
Acute myeloid leukemia,
Pharmaceutical industry “This is an important milestone that recognizes the transformative potential of our engineered TCR-T therapy candidates, TSC-100 and TSC-101, in multiple difficult-to-treat cancers.
Key Points:
- “This is an important milestone that recognizes the transformative potential of our engineered TCR-T therapy candidates, TSC-100 and TSC-101, in multiple difficult-to-treat cancers.
- TScan has developed two lead TCR-T therapy candidates, TSC-100 and TSC-101, that target minor histocompatibility antigens HA-1 and HA-2, respectively.
- On May 13, 2024, the Company provided an update on its Phase 1 heme malignancies program.
- A third control-arm patient required clinical intervention because of concerns of impending relapse, and a fourth control-arm patient died post-transplant.
WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been dosed in the Company’s Phase 1 trial evaluating TCR-T therapy for the treatment of solid tumors. The patient, diagnosed with metastatic melanoma, was dosed with TSC-203-A0201 targeting the cancer-associated antigen PReferentially expressed Antigen in MElanoma (PRAME).
Key Points:
- The patient, diagnosed with metastatic melanoma, was dosed with TSC-203-A0201 targeting the cancer-associated antigen PReferentially expressed Antigen in MElanoma (PRAME).
- “There is a lot of enthusiasm for this trial, and we are already manufacturing TCR-T products for three more patients.
- “Customized multiplex TCR-T therapy is designed to achieve durable responses by overcoming tumor heterogeneity and resistance that develops from either target or HLA loss.
- We look forward to sharing initial data from our solid tumor trial later this year.”
Retrieved on:
Wednesday, April 24, 2024
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.
Key Points:
- WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.
- Title: A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation
Title: Initial Data from a Phase 1, First-In-Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid Tumors
A copy of the presentation materials will be added to the “ Publications ” section of the Company’s website at tscan.com once presentations have concluded.
Retrieved on:
Wednesday, April 24, 2024
Sale,
Prospectus,
Cancer,
Morgan Stanley,
Vanderbilt Avenue,
Security (finance),
Form,
TD Securities,
Varick Street,
Patient,
2nd Floor,
S-3,
TCR,
Attention,
Therapy,
Telephone,
Needham & Company Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.
Key Points:
- Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.
- LifeSci Capital acted as lead manager, and BTIG, H.C. Wainwright & Co. and Needham & Company acted as co-managers for the offering.
- The offering was made only by means of a preliminary prospectus supplement and accompanying filed with the SEC.
- A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC.
WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.
Key Points:
- WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.
Sale,
Prospectus,
Cancer,
Morgan Stanley,
Vanderbilt Avenue,
Security (finance),
Form,
TD Securities,
Exercise,
Varick Street,
Patient,
2nd Floor,
TCR,
Attention,
Therapy,
Telephone,
Needham & Company In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.
Key Points:
- In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.
- The gross proceeds to TScan from this offering were approximately $150.1 million, prior to any exercise of the underwriters’ option to purchase additional shares of voting common stock and before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan.
- LifeSci Capital acted as lead manager, and BTIG, H.C. Wainwright & Co. and Needham & Company acted as co-managers for the offering.
- The offering was made only by means of a preliminary prospectus supplement and accompanying filed with the SEC.
Retrieved on:
Wednesday, April 17, 2024
Sale,
Prospectus,
Cancer,
Morgan Stanley,
Vanderbilt Avenue,
Security (finance),
Form,
TD Securities,
Varick Street,
Patient,
2nd Floor,
TCR,
Attention,
Therapy,
Telephone,
Needham & Company In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.
Key Points:
- In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.
- The gross proceeds to TScan from this offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriters’ option to purchase additional shares of voting common stock.
- The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.
- LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting as co-managers for the offering.
Sale,
Prospectus,
Cancer,
Morgan Stanley,
Vanderbilt Avenue,
Security (finance),
Form,
TD Securities,
Varick Street,
Patient,
2nd Floor,
S-3,
TCR,
Attention,
Therapy,
Telephone,
Needham & Company All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan.
Key Points:
- All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan.
- TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering.
- Morgan Stanley and TD Cowen are acting as joint book-running managers for the offering.
- LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting as co-managers for the offering.
Patient,
Cancer,
T-ALL,
MRD,
HLA,
Collection,
Trial of the century,
HCT,
AML,
IND,
Blood,
Syndrome,
Acute myeloid leukemia,
Acute leukemia,
Neoplasm,
TCR,
Therapy,
MDS,
ALL,
Medical imaging WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today provided an update on its solid tumor and heme malignancies clinical programs.
Key Points:
- “We continue to make meaningful progress across both our solid tumor and heme malignancies Phase 1 clinical programs.
- This should allow for rapid enrollment into the treatment protocol over the course of the year,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
- Phase 1 solid tumor clinical study has been initiated; first three patients expected to be dosed in early May 2024.
- Completion of Phase 1 enrollment and reporting of one-year clinical and translational data on initial patients is anticipated in the second half of 2024.
